Teladoc Health (NYSE:TDOC) Now Covered by The Goldman Sachs Group

The Goldman Sachs Group began coverage on shares of Teladoc Health (NYSE:TDOC - Free Report) in a research note issued to investors on Friday, Marketbeat Ratings reports. The firm issued a buy rating and a $14.00 price target on the health services provider's stock.

TDOC has been the topic of a number of other research reports. Truist Financial cut their price target on Teladoc Health from $15.00 to $10.00 and set a "hold" rating on the stock in a report on Friday, August 2nd. Evercore ISI boosted their price target on Teladoc Health from $8.00 to $9.00 and gave the stock an "in-line" rating in a research report on Tuesday, October 8th. Jefferies Financial Group raised their price target on Teladoc Health from $8.00 to $10.00 and gave the company a "hold" rating in a report on Tuesday, September 17th. Needham & Company LLC restated a "hold" rating on shares of Teladoc Health in a research note on Thursday, August 1st. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of Teladoc Health from $10.00 to $12.00 and gave the company a "hold" rating in a research report on Friday, November 1st. Fourteen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $12.08.

Teladoc Health Stock Performance

NYSE:TDOC traded up $0.29 during midday trading on Friday, reaching $9.25. 8,727,455 shares of the company traded hands, compared to its average volume of 5,522,220. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -1.55 and a beta of 0.90. The company has a fifty day moving average price of $8.86 and a 200 day moving average price of $9.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.73 and a quick ratio of 1.69. Teladoc Health has a twelve month low of $6.76 and a twelve month high of $22.54.

Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.10. The company had revenue of $640.51 million during the quarter, compared to the consensus estimate of $630.50 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. On average, analysts expect that Teladoc Health will post -1.19 EPS for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In related news, CFO Mala Murthy sold 8,750 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total transaction of $62,650.00. Following the completion of the sale, the chief financial officer now directly owns 85,767 shares in the company, valued at approximately $614,091.72. This trade represents a 9.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Thomas Mckinley bought 4,000 shares of the stock in a transaction on Thursday, September 12th. The stock was purchased at an average price of $7.69 per share, for a total transaction of $30,760.00. Following the purchase, the director now directly owns 39,077 shares of the company's stock, valued at approximately $300,502.13. This represents a 11.40 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 20,051 shares of company stock valued at $143,565 in the last 90 days. 0.95% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Teladoc Health

Institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. increased its holdings in Teladoc Health by 57.8% in the third quarter. Point72 Asset Management L.P. now owns 8,366,295 shares of the health services provider's stock worth $76,803,000 after buying an additional 3,063,172 shares during the last quarter. Rubric Capital Management LP bought a new stake in Teladoc Health in the second quarter worth approximately $45,267,000. Clearline Capital LP increased its stake in shares of Teladoc Health by 395.6% during the 2nd quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider's stock worth $42,682,000 after purchasing an additional 3,483,665 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Teladoc Health during the 3rd quarter valued at $15,801,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Teladoc Health by 15.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,701,161 shares of the health services provider's stock valued at $15,617,000 after purchasing an additional 228,004 shares during the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.